Search - tctmd.com

Displaying 141 - 160 of 201

Sort: Relevancy | Date

News Daily News

Case Study Highlights Risks for A-fib Patients Undergoing PCI in Absence of Evidence-Based Guidelines

Yael L. Maxwell

December 14, 2015

News Industry News

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

October 20, 2015

News Conference News TCT 2015

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Yael L. Maxwell

October 15, 2015

News Industry News

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

September 09, 2015

News Conference News ESC 2015

NSAIDs Plus Anticoagulants a Bad Combination

Caitlin E. Cox

September 01, 2015

News Daily News

年长房颤 PCI 患者在接受三联疗法时，其血栓状况未得到改善，且出血事件增加

August 04, 2015

News Daily News

Triple Therapy Yields No Thrombotic Benefit, More Bleeding in Older PCI Patients With A-fib

August 04, 2015

News Daily News

El Tratamiento Triple No ofrece Beneficio Trombótico y Sí Más Hemorragias en Pacientes Ancianos con FA sometidos a PCI

August 04, 2015

News Industry News

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

July 29, 2015

News Industry News

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

July 13, 2015

News Daily News

房颤患者过渡治疗无法预防血栓栓塞，且会增加出血

Yael L. Maxwell

July 10, 2015

News Industry News

UK launch for Daiichi's bloodthinner Lixiana

July 10, 2015

News Daily News

La Terapia Puente para Pacientes con FA No Previene los Tromboembolismos y Aumenta las Hemorragias

Yael L. Maxwell

July 10, 2015

News Daily News

Bridging Therapy for A-fib Patients Fails to Prevent Thromboembolism, Increases Bleeding

Yael L. Maxwell

July 10, 2015

News Daily News

ISAR-TRIPLE 已发布：6 周与 6 个月三联疗法比较并无净收益

April 29, 2015

News Daily News

ISAR-TRIPLE Published: No Net Gain for 6 Weeks vs 6 Months of Triple Therapy

April 29, 2015

News Daily News

ISAR-TRIPLE Publicado: No hay Beneficio Neto durante 6 Semanas frente a 6 Meses a Tratamiento Triple

April 29, 2015

Presentation TCT 2014

Thoughtful Insights

Presenter: Daniel I. Simon

September 17, 2014

Presentation TCT 2014

Case Presentation

Presenter: Thomas D. Stuckey

September 17, 2014

Presentation TCT 2014

TCT 475: Triple Antithrombotic Therapy Versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Dong Oh Kang

September 15, 2014

Advertisement

Case Study Highlights Risks for A-fib Patients Undergoing PCI in Absence of Evidence-Based Guidelines

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

NSAIDs Plus Anticoagulants a Bad Combination

年长房颤 PCI 患者在接受三联疗法时，其血栓状况未得到改善，且出血事件增加

Triple Therapy Yields No Thrombotic Benefit, More Bleeding in Older PCI Patients With A-fib

El Tratamiento Triple No ofrece Beneficio Trombótico y Sí Más Hemorragias en Pacientes Ancianos con FA sometidos a PCI

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

房颤患者过渡治疗无法预防血栓栓塞，且会增加出血

UK launch for Daiichi's bloodthinner Lixiana

La Terapia Puente para Pacientes con FA No Previene los Tromboembolismos y Aumenta las Hemorragias

Bridging Therapy for A-fib Patients Fails to Prevent Thromboembolism, Increases Bleeding

ISAR-TRIPLE 已发布：6 周与 6 个月三联疗法比较并无净收益

ISAR-TRIPLE Published: No Net Gain for 6 Weeks vs 6 Months of Triple Therapy

ISAR-TRIPLE Publicado: No hay Beneficio Neto durante 6 Semanas frente a 6 Meses a Tratamiento Triple

Thoughtful Insights

Case Presentation

TCT 475: Triple Antithrombotic Therapy Versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content